<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:52:36Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9710690" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9710690</identifier>
        <datestamp>2022-12-01</datestamp>
        <setSpec>cid</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Clin Infect Dis</journal-id>
              <journal-id journal-id-type="iso-abbrev">Clin Infect Dis</journal-id>
              <journal-id journal-id-type="publisher-id">cid</journal-id>
              <journal-title-group>
                <journal-title>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">1058-4838</issn>
              <issn pub-type="epub">1537-6591</issn>
              <publisher>
                <publisher-name>Oxford University Press</publisher-name>
                <publisher-loc>US</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9710690</article-id>
              <article-id pub-id-type="pmcid">PMC9710690</article-id>
              <article-id pub-id-type="pmc-uid">9710690</article-id>
              <article-id pub-id-type="pmid">35941737</article-id>
              <article-id pub-id-type="pmid">35941737</article-id>
              <article-id pub-id-type="doi">10.1093/cid/ciac284</article-id>
              <article-id pub-id-type="publisher-id">ciac284</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Major Article</subject>
                  <subj-group subj-group-type="category-toc-heading">
                    <subject>Original Article</subject>
                  </subj-group>
                </subj-group>
                <subj-group subj-group-type="category-taxonomy-collection">
                  <subject>AcademicSubjects/MED00290</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Initiating Intramuscular Depot Medroxyprogesterone Acetate Increases
Frequencies of Th17-like Human Immunodeficiency Virus Target Cells in the Genital Tract of
Women in South Africa: A Randomized Trial</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8471-163X</contrib-id>
                  <name>
                    <surname>Bunjun</surname>
                    <given-names>Rubina</given-names>
                  </name>
                  <aff><institution>Institute of Infectious Disease and Molecular Medicine, Department of
Pathology, University of Cape Town</institution>, <addr-line>Cape Town</addr-line>,
<country country="ZA">South Africa</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ramla</surname>
                    <given-names>Tanko F</given-names>
                  </name>
                  <aff><institution>Institute of Infectious Disease and Molecular Medicine, Department of
Pathology, University of Cape Town</institution>, <addr-line>Cape Town</addr-line>,
<country country="ZA">South Africa</country></aff>
                  <aff><institution>The Medical Research Centre, Institute of Medical Research and Medicinal
Plant Studies (IMPM), Ministry of Scientific Research and Innovation</institution>,
<addr-line>Yaoundé</addr-line>, <country country="CM">Cameroon</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jaumdally</surname>
                    <given-names>Shameem Z</given-names>
                  </name>
                  <aff><institution>Institute of Infectious Disease and Molecular Medicine, Department of
Pathology, University of Cape Town</institution>, <addr-line>Cape Town</addr-line>,
<country country="ZA">South Africa</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Noël-Romas</surname>
                    <given-names>Laura</given-names>
                  </name>
                  <aff><institution>Center for Global Health and Diseases, Case Western Reserve
University</institution>, <addr-line>Cleveland, Ohio</addr-line>, <country country="US">USA</country></aff>
                  <aff><institution>Department of Obstetrics and Gynecology, University of
Manitoba</institution>, <addr-line>Winnipeg</addr-line>, <country country="CA">Canada</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ayele</surname>
                    <given-names>Hossaena</given-names>
                  </name>
                  <aff><institution>Center for Global Health and Diseases, Case Western Reserve
University</institution>, <addr-line>Cleveland, Ohio</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Brown</surname>
                    <given-names>Bryan P</given-names>
                  </name>
                  <aff><institution>Seattle Children’s Research Institute</institution>, <addr-line>Seattle,
Washington</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gamieldien</surname>
                    <given-names>Hoyam</given-names>
                  </name>
                  <aff><institution>Institute of Infectious Disease and Molecular Medicine, Department of
Pathology, University of Cape Town</institution>, <addr-line>Cape Town</addr-line>,
<country country="ZA">South Africa</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Harryparsad</surname>
                    <given-names>Rushil</given-names>
                  </name>
                  <aff><institution>Institute of Infectious Disease and Molecular Medicine, Department of
Pathology, University of Cape Town</institution>, <addr-line>Cape Town</addr-line>,
<country country="ZA">South Africa</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dabee</surname>
                    <given-names>Smritee</given-names>
                  </name>
                  <aff><institution>Institute of Infectious Disease and Molecular Medicine, Department of
Pathology, University of Cape Town</institution>, <addr-line>Cape Town</addr-line>,
<country country="ZA">South Africa</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nair</surname>
                    <given-names>Gonasagrie</given-names>
                  </name>
                  <aff><institution>Desmond Tutu HIV Foundation (DTHF)</institution>, <addr-line>Cape
Town</addr-line>, <country country="ZA">South Africa</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Onono</surname>
                    <given-names>Maricianah</given-names>
                  </name>
                  <aff><institution>Kenya Medical Research Institute</institution>,
<addr-line>Nairobi</addr-line>, <country country="KE">Kenya</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Palanee-Phillips</surname>
                    <given-names>Thesla</given-names>
                  </name>
                  <aff><institution>Wits Reproductive Health and HIV Institute (WHRI)</institution>,
<addr-line>Johannesburg</addr-line>, <country country="ZA">South
Africa</country></aff>
                  <aff><institution>University of Washington</institution>, <addr-line>Seattle,
Washington</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Scoville</surname>
                    <given-names>Catilin W</given-names>
                  </name>
                  <aff><institution>University of Washington</institution>, <addr-line>Seattle,
Washington</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Heller</surname>
                    <given-names>Kate B</given-names>
                  </name>
                  <aff><institution>University of Washington</institution>, <addr-line>Seattle,
Washington</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Baeten</surname>
                    <given-names>Jared M</given-names>
                  </name>
                  <aff><institution>University of Washington</institution>, <addr-line>Seattle,
Washington</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bosinger</surname>
                    <given-names>Steven E</given-names>
                  </name>
                  <aff><institution>Emory University</institution>, <addr-line>Atlanta, Georgia</addr-line>,
<country country="US">USA</country></aff>
                  <aff><institution>Yerkes National Primate Research Center</institution>, <addr-line>Atlanta,
Georgia</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Burgener</surname>
                    <given-names>Adam</given-names>
                  </name>
                  <aff><institution>Center for Global Health and Diseases, Case Western Reserve
University</institution>, <addr-line>Cleveland, Ohio</addr-line>, <country country="US">USA</country></aff>
                  <aff><institution>Department of Obstetrics and Gynecology, University of
Manitoba</institution>, <addr-line>Winnipeg</addr-line>, <country country="CA">Canada</country></aff>
                  <aff><institution>Unit of Infectious Diseases, Department of Medicine Solna, Center for
Molecular Medicine, Karolinska Institute, Karolinska University
Hospital</institution>, <addr-line>Stockholm</addr-line>, <country country="SE">Sweden</country></aff>
                </contrib>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Passmore</surname>
                    <given-names>Jo-Ann S</given-names>
                  </name>
                  <aff><institution>Institute of Infectious Disease and Molecular Medicine, Department of
Pathology, University of Cape Town</institution>, <addr-line>Cape Town</addr-line>,
<country country="ZA">South Africa</country></aff>
                  <aff><institution>National Health Laboratory Services (NHLS)</institution>, <addr-line>Cape
Town</addr-line>, <country country="ZA">South Africa</country></aff>
                  <xref rid="ciac284-cor1" ref-type="corresp"/>
                  <!--jo-ann.passmore@uct.ac.za-->
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jaspan</surname>
                    <given-names>Heather</given-names>
                  </name>
                  <aff><institution>Institute of Infectious Disease and Molecular Medicine, Department of
Pathology, University of Cape Town</institution>, <addr-line>Cape Town</addr-line>,
<country country="ZA">South Africa</country></aff>
                  <aff><institution>Seattle Children’s Research Institute</institution>, <addr-line>Seattle,
Washington</addr-line>, <country country="US">USA</country></aff>
                  <aff><institution>University of Washington</institution>, <addr-line>Seattle,
Washington</addr-line>, <country country="US">USA</country></aff>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Heffron</surname>
                    <given-names>Renee</given-names>
                  </name>
                  <aff><institution>University of Washington</institution>, <addr-line>Seattle,
Washington</addr-line>, <country country="US">USA</country></aff>
                  <xref rid="ciac284-FM1" ref-type="author-notes"/>
                </contrib>
              </contrib-group>
              <author-notes>
                <corresp id="ciac284-cor1">Correspondence: J.-A. S. Passmore, Institute of Infectious
Disease and Molecular Medicine, Division of Virology, Faculty of Health Sciences,
University of Cape Town, Observatory 7925, South Africa
(<email>jo-ann.passmore@uct.ac.za</email>).</corresp>
                <fn id="ciac284-FM1" fn-type="COI-statement">
                  <p><bold><italic toggle="yes">Potential conflicts of interest.</italic></bold> J.-A. S. P. reports the following grants or contracts all paid to the author’s
institution and unrelated to this work: Bill and Melinda Gates Foundation (BMGF) Vaginal
Microbiome Research Consortium (VMRC) Planning Grant (Principal Investigator [PI]: Dr
Jo-Ann Passmore. Co-PI: Dr Leila Mansoor; Co-Investigators: Nigel Garrett, Cheryl
Baxter, Sinaye Ngcapu, Lenine Liebenberg, Aida Sivro, Brian Kullin, Anna Happel. US
$512 088 for 12 months); European and Developing Countries Clinical Trials Partnership
(EDCTP) RIA2020I (3297) for project entitled “GIFT for HIV Prevention” (Passmore, Co-PI:
Masson (Burnett Institute, Australia); Co-Investigators: Suzanna Francis and Katharina
Kranzer (The London School of Hygiene &amp; Tropical Medicine, UK), Janneke van der
Wijgert (University Medical Center, Netherlands), Tania Crucitti (Institute Pasteur
Madegascar, Madagascar), David Anderson (Burnet Institute, Australia), Ayako Honda
(Sophia University, Japan), Chido Dziva-Chikwari (The Organization for Public Health
Interventions and Development, Zimbabwe), Katherine Gill (Desmond Tutu Health
Foundation, South Africa) (Euro 3 508 462 for 36 months); BMGF Calestous Juma Scientific
Leadership Award for project entitled “VMRC4Africa” (PI: Passmore. US $1 million over 5
years); and Medical Research Council Strategic Health Innovation Partnerships (South
Africa), Genital inflammation test for females (GIFT) (PIs: Dr Jo-Ann Passmore and Dr
Lindi Masson, ZAR 5 million per year for 4 years). J.-A. S. P. also reports a patent
granted in 2022 with no payment made (Method for diagnosing an inflammatory condition in
the female genital tract; PCT/IB2014/065740; EP3063542B1); and unpaid participation on a
Data Safety Monitoring Board (DSMB) or Advisory Board for a phase 2 placebo-controlled
randomized trial of LACTIN-V (<italic toggle="yes">Lactobacillus crispatus</italic> CTV-05) among
women at high risk of HIV acquisition in Durban, South Africa (Chair DSMB; Cohen et al
National Institute of Child Health and Human Development [NICHD] grant 1R01HD098978). R.
H. reports grants or contracts unrelated to this work and paid to the author’s
institution from the NICHD. H. J. reports support for attending meetings and/or travel
from World Vaccine Congress. S. E. B. reports grants or contracts unrelated to this work
from the National Institutes of Health (NIH R01 HD089831): Effects of Hormonal
Contraceptives on Genital Immunity and HIV Susceptibility. B. P. B. reports support for
attending meetings and/or travel (NIH R01HD089831). J. M. H. reports grants to
institution unrelated to this work from the NIH, USAID, and BMGF; and employment (with
stocks and stock options) with Gilead Sciences. All other authors report no potential
conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential
Conflicts of Interest. Conflicts that the editors consider relevant to the content of
the manuscript have been disclosed.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="collection">
                <day>01</day>
                <month>12</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="epub" iso-8601-date="2022-08-09">
                <day>09</day>
                <month>8</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>09</day>
                <month>8</month>
                <year>2022</year>
              </pub-date>
              <volume>75</volume>
              <issue>11</issue>
              <fpage>2000</fpage>
              <lpage>2011</lpage>
              <history>
                <date date-type="received">
                  <day>15</day>
                  <month>1</month>
                  <year>2022</year>
                </date>
                <date date-type="editorial-decision">
                  <day>01</day>
                  <month>4</month>
                  <year>2022</year>
                </date>
                <date date-type="corrected-typeset">
                  <day>09</day>
                  <month>8</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© The Author(s) 2022. Published by Oxford University Press on behalf of
Infectious Diseases Society of America.</copyright-statement>
                <copyright-year>2022</copyright-year>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits
non-commercial reproduction and distribution of the work, in any medium, provided the
original work is not altered or transformed in any way, and that the work is properly
cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
                </license>
              </permissions>
              <self-uri xlink:href="ciac284.pdf"/>
              <related-article related-article-type="correction-forward" ext-link-type="doi" id="RA1" xlink:href="10.1093/cid/ciac898"/>
              <abstract>
                <title>Abstract</title>
                <sec id="s2">
                  <title>Background</title>
                  <p>Cervicovaginal CD4+ T cells are preferential targets for human immunodeficiency virus
(HIV) infection and have consequently been used as a proxy measure for HIV
susceptibility. The ECHO randomized trial offered a unique opportunity to consider the
association between contraceptives and Th17-like cells within a trial designed to
evaluate HIV risk. In a mucosal substudy of the ECHO trial, we compared the impact of
initiating intramuscular depot medroxyprogesterone acetate (DMPA-IM), copper-IUD, and
the levonorgestrel (LNG) implant on cervical T cells.</p>
                </sec>
                <sec id="s3">
                  <title>Methods</title>
                  <p>Cervical cytobrushes from 58 women enrolled in the ECHO trial were collected at
baseline and 1 month after contraceptive initiation. We phenotyped cervical T cells
using multiparameter flow cytometry, characterized the vaginal microbiome using 16s
sequencing, and determined proteomic signatures associated with Th17-like cells using
mass spectrometry.</p>
                </sec>
                <sec id="s4">
                  <title>Results</title>
                  <p>Unlike the LNG implant or copper-IUD, DMPA-IM was associated with higher frequencies of
cervical Th17-like cells within 1 month of initiation (<italic toggle="yes">P</italic> = .012),
including a highly susceptible, activated population co-expressing CD38, CCR5, and α4β7
(<italic toggle="yes">P</italic> = .003). After 1 month, women using DMPA-IM also had more
Th17-like cells than women using the Cu-IUD (<italic toggle="yes">P</italic> = .0002) or LNG implant
(<italic toggle="yes">P</italic> = .04). Importantly, in women using DMPA-IM, proteomic signatures
signifying enhanced mucosal barrier function were associated with the increased
abundance of Th17-like cells. We also found that a
non–<italic toggle="yes">Lactobacillus-</italic>dominant microbiome at baseline was associated with
more Th17-like cells post–DMPA-IM (<italic toggle="yes">P</italic> = .03), although this did not
influence barrier function.</p>
                </sec>
                <sec id="s5">
                  <title>Conclusions</title>
                  <p>Our data suggest that DMPA-IM–driven accumulation of HIV-susceptible Th17-like cells
might be counteracted by their role in maintaining mucosal barrier integrity.</p>
                </sec>
                <sec id="s6">
                  <title>Clinical Trials Registration</title>
                  <p>NCT02550067.</p>
                </sec>
              </abstract>
              <abstract abstract-type="teaser">
                <p>Cervicovaginal Th17-like cells significantly increased in women after initiation of
DMPA-IM but not the Cu-IUD or LNG-implant. Proteomic analyses suggest that this
DMPA-driven accumulation of HIV susceptible Th17-like cells might be counteracted by their
role in maintaining mucosal barrier integrity.</p>
              </abstract>
              <kwd-group>
                <kwd>hormonal contraception</kwd>
                <kwd>HIV risk</kwd>
                <kwd>Th17 cells</kwd>
                <kwd>mucosal barrier integrity</kwd>
              </kwd-group>
              <funding-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>Bill &amp; Melinda Gates Foundation</institution>
                      <institution-id institution-id-type="doi">10.13039/100000865</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>US Agency for International Development</institution>
                      <institution-id institution-id-type="doi">10.13039/100000200</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>President’s Emergency Plan for AIDS Relief</institution>
                      <institution-id institution-id-type="doi">10.13039/100009054</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>Swedish International Development Cooperation Agency</institution>
                      <institution-id institution-id-type="doi">10.13039/100004441</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>South African Medical Research Council</institution>
                      <institution-id institution-id-type="doi">10.13039/501100001322</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>UN Population Fund</institution>
                      <institution-id institution-id-type="doi">10.13039/100006661</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>Government of South Africa</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>US Agency for International Development</institution>
                      <institution-id institution-id-type="doi">10.13039/100000200</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>US National Institute of Child Health and Human Development</institution>
                      <institution-id institution-id-type="doi">10.13039/100000071</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Institutes of Health</institution>
                      <institution-id institution-id-type="doi">10.13039/100000002</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R01HD089831-05</award-id>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>ECHO Biological Mechanisms Ancillary Study</institution>
                    </institution-wrap>
                  </funding-source>
                </award-group>
                <award-group award-type="grant">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Institutes of Health</institution>
                      <institution-id institution-id-type="doi">10.13039/100000002</institution-id>
                    </institution-wrap>
                  </funding-source>
                </award-group>
              </funding-group>
              <counts>
                <page-count count="12"/>
              </counts>
            </article-meta>
          </front>
          <body>
            <p>The randomized Evidence for Contraceptive Options and HIV Outcomes (ECHO) trial found no
differences in human immunodeficiency virus (HIV) incidence between women assigned to
intramuscular depot medroxyprogesterone acetate (DMPA-IM), a copper T intrauterine device
(Cu-IUD), or 2-rod levonorgestrel (LNG) implant [<xref rid="ciac284-B1" ref-type="bibr">1</xref>], adding to our understanding of contraceptive use and HIV susceptibility [<xref rid="ciac284-B2" ref-type="bibr">2–5</xref>]. Importantly,
ECHO offered a unique opportunity to explore contraceptive-induced biological changes,
particularly those pertinent to HIV susceptibility. Cervical CD4+ T cells, especially T-helper
17 (Th17) cells, are preferential targets for HIV due to their cell-surface markers [<xref rid="ciac284-B6" ref-type="bibr">6–10</xref>],
and have been used as a proxy for HIV susceptibility [<xref rid="ciac284-B11" ref-type="bibr">11</xref>]. An increase in these HIV target cells, whether a result of contraceptive use,
or other factors, would consequently increase HIV risk. However, Th17 cells may also play a
protective role in the context of HIV acquisition, by mediating mucosal immunity and barrier
repair [<xref rid="ciac284-B12" ref-type="bibr">12</xref>, <xref rid="ciac284-B13" ref-type="bibr">13</xref>]. It remains vital to understand the relationship between
contraceptive use and Th17 target cells, particularly within the ECHO trial where HIV
seroconversion was an endpoint. Therefore, we conducted a nested substudy evaluating the
impact of contraceptive initiation on cervical Th17-like cells.</p>
            <sec sec-type="methods" id="ciac284-s1">
              <title>METHODS</title>
              <sec id="ciac284-s1.1">
                <title>Ethics Statement</title>
                <p>This study was approved by the Human Research Ethics Committees of the Universities of
Cape Town (HREC 371/2015) and Washington (STUDY00000261) and FHI360 (523201). All women
provided informed written consent.</p>
              </sec>
              <sec id="ciac284-s1.2">
                <title>ECHO Trial</title>
                <p>The ECHO trial (Clinicaltrials.gov ID NCT02550067) enrolled 7829 women to 3 contraceptive
arms: the Cu-IUD, DMPA-IM, and LNG-implant [<xref rid="ciac284-B1" ref-type="bibr">1</xref>]. These women were sexually active, HIV seronegative, and seeking
contraception. Women were excluded if they received DMPA, norethisterone enanthate
(Net-EN), an implant, or IUD in the previous 6 months; were pregnant; had a hysterectomy;
or had known sexually transmitted infections (STIs). At enrollment, participants were
screened for <italic toggle="yes">Chlamydia trachomatis</italic> (CT) and <italic toggle="yes">Neisseria
gonorrhoeae</italic> (NG). Treatment was provided for curable STIs and bacterial
vaginosis diagnosed syndromically, according to national guidelines or, for CT/NG,
diagnosed etiologically.</p>
              </sec>
              <sec id="ciac284-s1.3">
                <title>Substudy of Biological Mechanisms</title>
                <p>Cervical cytobrushes from 80 Cape Town women were collected and processed [<xref rid="ciac284-B14" ref-type="bibr">14</xref>]. Cervicovaginal secretions were collected
by a disposable menstrual cup inserted for 45 minutes, then removed and placed in a 50-mL
sterile tube. A lateral vaginal wall swab was collected through use of a speculum and
placed into Digene transport media. Samples were transported to the laboratory within 4
hours of collection, at 4°C. Menstrual cup secretions were processed [<xref rid="ciac284-B14" ref-type="bibr">14</xref>], diluted 4:1 in phosphate-buffered saline,
and stored at −80°C. The swab was stored at −80°C. Researchers were blinded to the
assigned contraceptive arm until the analyses were complete.</p>
              </sec>
              <sec id="ciac284-s1.4">
                <title>Multiparameter Flow Cytometry</title>
                <p>Cytobrush cells were phenotyped ex vivo at enrollment and post–contraception initiation
from the same 80 women, of whom 63 women completed both study visits (Cu-IUD, n = 24;
DMPA-IM, n = 22; LNG implant, n = 17). Cytobrushes were flushed approximately 30 times
with transport media using a disposable Pasteur pipette before transferring to a fresh
tube and flushing with an additional 6 mL of media. Cells were centrifuged at 300 ×
<italic toggle="yes">g</italic> for 10 minutes at 4°C. The cell pellet was stained with CD3, CD4,
CD8, CD38, HLA-DR, CCR6, CCR10, CCR5, and α4β7 (<xref rid="sup1" ref-type="supplementary-material">Supplementary Table 1</xref>), then acquired on a BD LSRII using FACSDiva.
Post-compensation analysis was performed using FlowJo (TreeStar), Pestle and Spice [<xref rid="ciac284-B15" ref-type="bibr">15</xref>]. Gating was based on fluorescence-minus-one
controls. Samples with less than 100 live CD3+ events were excluded from further analyses
[<xref rid="ciac284-B16" ref-type="bibr">16</xref>], resulting in n = 58 participants
with matched samples at 2 time points (Cu-IUD, n = 23; DMPA-IM, n = 20; LNG implant, n =
15). Gating and analysis were independently checked.</p>
              </sec>
              <sec id="ciac284-s1.5">
                <title>Microbial 16S rRNA Gene Sequencing</title>
                <p>Bacterial gDNA was extracted using the DNeasy Powersoil HTP 96 kit (Qiagen) from thawed
lateral wall swabs following the manufacturer’s protocol. The V3-V4 hypervariable region
of the bacterial 16S rRNA gene was amplified using modified universal primers. Dual-index
barcodes and Illumina sequencing adaptors were attached using polymerase chain reaction
(PCR) primers [<xref rid="ciac284-B17" ref-type="bibr">17</xref>], and amplicons were
pooled in equimolar amounts for sequencing with Illumina MiSeq platform (300-bp
paired-end). Following demultiplexing, raw reads were processed using DADA2 and samples
with less than 2000 reads were excluded. Taxonomic annotation was carried out using the
Ribosomal Database Project’s Naïve Bayesian classifier. Sequence classification was
trained against the Silva training set version 132 (<ext-link xlink:href="https://github.com/itsmisterbrown/updated_16S_dbs" ext-link-type="uri">https://github.com/itsmisterbrown/updated_16S_dbs</ext-link>). Run-specific
contamination filtering was performed using microfiltR (<ext-link xlink:href="https://github.com/itsmisterbrown/microfiltR" ext-link-type="uri">https://github.com/itsmisterbrown/microfiltR</ext-link>). Sequencing runs were merged
using custom scripts (<ext-link xlink:href="https://github.com/itsmisterbrown/marker_gene_dataset_merging_functions" ext-link-type="uri">https://github.com/itsmisterbrown/marker_gene_dataset_merging_functions</ext-link>).</p>
              </sec>
              <sec id="ciac284-s1.6">
                <title>Classification of Microbial Communities</title>
                <p>Partition around medoids (PAM) clustering of community profiles using Bray-Curtis
distance on relative abundance transformed taxonomic profiles resulted in the
identification of 5 community state types (CSTs) [<xref rid="ciac284-B18" ref-type="bibr">18</xref>]. CSTs III-A and I-B were dominated by <italic toggle="yes">Lactobacillus</italic> taxa.
CST IV-B was primarily comprised <italic toggle="yes">Gardnerella vaginalis</italic>. CSTs IV-A and
IV-D were the most diverse and associated with clinical bacterial vaginosis diagnosis.</p>
              </sec>
              <sec id="ciac284-s1.7">
                <title>Proteomic Analysis of Cervicovaginal Secretions</title>
                <p>Cervicovaginal secretions were analyzed by label-free tandem mass spectrometry as
described previously [<xref rid="ciac284-B19" ref-type="bibr">19</xref>]. Samples were
centrifuged at 14 000 × <italic toggle="yes">g</italic> for 20 minutes at 4°C, followed by protein
determination by bicinchoninic acid (BCA) assay (Millipore). Protein from each sample
(25 g) was denatured using urea exchange buffer (8 M, 50 mM HEPES
[4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid], pH 8.0) then filtered using Nanosep
filter cartridges (10 kDa). Samples were reduced and alkylated with 25 mM DTT
(dithiothreitol) and 50 mM iodoacetamide (IAA), respectively, before overnight trypsin
digestion (2 μg/100 μg protein). Desalting of peptides was performed by reverse-phase
liquid chromatography (Agilent 1200). Equal amounts of peptide were then analyzed using a
nano-flow Easy 1000 system connected in-line to an Orbitrap Q Exactive mass spectrometer
(ThermoFisher Scientific). Database searches were carried out using the Mascot search
engine (version 2.4; Matrix Science) using the SwisProtKB Human database (UniProt, 2018).
Results were analyzed using Scaffold Q+ software (version 4.9.0; Proteome Software), and
protein identifications were restricted to those that passed a ≤1% false discovery rate
(FDR) at the protein level, ≤0.1% FDR at the peptide level, and had more than 2 unique
peptides/protein. Label-free protein abundance was calculated using Progenesis QI software
(Nonlinear Dynamics).</p>
              </sec>
              <sec id="ciac284-s1.8">
                <title>Statistical Analysis</title>
                <p>Prism 9 (GraphPad) was used for Wilcoxon matched pairs, Mann–Whitney <italic toggle="yes">U</italic>
tests, and Kruskal–Wallis to compare frequencies of cells. Regression analyses between
Th17-like cells and the microbiome were performed in SPSS Statistics version 27 (IBM
Corporation). Post–DMPA-IM protein levels and Th17-like cells were normalized by baseline
to calculate a log<sub>2</sub> fold-change (L2FC) value. Protein L2FCs were correlated to
their matched Th17 L2FC value using the Pearson’s method (<italic toggle="yes">P</italic> &lt; .05).
Pathway analysis was performed on proteins that passed a critical value of α = 0.05 using
both Ingenuity Pathway Analysis (QIAGEN) and DAVID Knowledgebase (Bioinformatics). The
Benjamini–Hochberg method was used to adjust for multiple testing. A <italic toggle="yes">P</italic>
value of &lt;0.05 was considered statistically significant.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="ciac284-s2">
              <title>RESULTS</title>
              <p>Baseline and 1-month cytobrushes were collected from 80 Cape Town women, a median of 4.3
weeks apart (interquartile range [IQR], 4–9.4 weeks). Participants were similar between
arms, with no differences in age, body mass index, or STI prevalence (<xref rid="ciac284-T1" ref-type="table">Table 1</xref>).</p>
              <table-wrap position="float" id="ciac284-T1">
                <label>Table 1.</label>
                <caption>
                  <p>Baseline Characteristics According to Randomized Arm</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <colgroup span="1">
                    <col valign="top" align="left" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                    <col valign="top" align="center" span="1"/>
                  </colgroup>
                  <thead>
                    <tr>
                      <th rowspan="1" colspan="1"/>
                      <th align="center" rowspan="1" colspan="1">Cu-IUD (n = 23)</th>
                      <th align="center" rowspan="1" colspan="1">DMPA-IM (n = 20)</th>
                      <th align="center" rowspan="1" colspan="1">LNG Implant (n = 15)</th>
                      <th align="center" rowspan="1" colspan="1">
                        <italic toggle="yes">P</italic>
                      </th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td rowspan="1" colspan="1">Age,<sup><xref rid="ciac284-tblfn2" ref-type="table-fn">a</xref></sup> years</td>
                      <td rowspan="1" colspan="1">22 (20–28)</td>
                      <td rowspan="1" colspan="1">24 (22–25)</td>
                      <td rowspan="1" colspan="1">22 (20–25)</td>
                      <td rowspan="1" colspan="1">0.80</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">BMI,<sup><xref rid="ciac284-tblfn2" ref-type="table-fn">a</xref></sup>
kg/m<sup>2</sup></td>
                      <td rowspan="1" colspan="1">29 (26–38)</td>
                      <td rowspan="1" colspan="1">27 (23–32)</td>
                      <td rowspan="1" colspan="1">26 (22–32)</td>
                      <td rowspan="1" colspan="1">0.14</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">Days since last menstrual period<sup>a</sup></td>
                      <td rowspan="1" colspan="1">17 (11–27)</td>
                      <td rowspan="1" colspan="1">20.5 (10.3–29)</td>
                      <td rowspan="1" colspan="1">21 (12.3–30.5)</td>
                      <td rowspan="1" colspan="1">0.51</td>
                    </tr>
                    <tr>
                      <td colspan="5" rowspan="1">Genital infections, n (%)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">
                        <italic toggle="yes"> Chlamydia trachomatis</italic>
                      </td>
                      <td rowspan="1" colspan="1">4 (17.4%)</td>
                      <td rowspan="1" colspan="1">6 (30%)</td>
                      <td rowspan="1" colspan="1">4 (26.7%)</td>
                      <td rowspan="1" colspan="1">0.63</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1">
                        <italic toggle="yes"> Neisseria gonorrhoeae</italic>
                      </td>
                      <td rowspan="1" colspan="1">2 (8.7%)</td>
                      <td rowspan="1" colspan="1">3 (15%)</td>
                      <td rowspan="1" colspan="1">1 (6.7%)</td>
                      <td rowspan="1" colspan="1">0.75</td>
                    </tr>
                    <tr>
                      <td colspan="5" rowspan="1">Bacterial vaginosis (BV),<sup><xref rid="ciac284-tblfn3" ref-type="table-fn">b</xref></sup> n (%)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Positive</td>
                      <td rowspan="1" colspan="1">10 (43.5%)</td>
                      <td rowspan="1" colspan="1">10 (50%)</td>
                      <td rowspan="1" colspan="1">7 (46.7%)</td>
                      <td rowspan="1" colspan="1">0.73</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Intermediate</td>
                      <td rowspan="1" colspan="1">3 (13%)</td>
                      <td rowspan="1" colspan="1">2 (10%)</td>
                      <td rowspan="1" colspan="1">0 (0%)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Negative</td>
                      <td rowspan="1" colspan="1">10 (43.5%)</td>
                      <td rowspan="1" colspan="1">8 (40%)</td>
                      <td rowspan="1" colspan="1">8 (53.3%)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td colspan="5" rowspan="1">Demographics, n (%)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Never married</td>
                      <td rowspan="1" colspan="1">23 (100%)</td>
                      <td rowspan="1" colspan="1">20 (100%)</td>
                      <td rowspan="1" colspan="1">14 (93.3)</td>
                      <td rowspan="1" colspan="1">0.26</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Married</td>
                      <td rowspan="1" colspan="1">0 (0%)</td>
                      <td rowspan="1" colspan="1">0 (0%)</td>
                      <td rowspan="1" colspan="1">1 (6.7%)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Primary school education</td>
                      <td rowspan="1" colspan="1">1 (4.3%)</td>
                      <td rowspan="1" colspan="1">0 (0%)</td>
                      <td rowspan="1" colspan="1">0 (0%)</td>
                      <td rowspan="1" colspan="1">0.71</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Secondary education</td>
                      <td rowspan="1" colspan="1">22 (95.7%)</td>
                      <td rowspan="1" colspan="1">20 (100%)</td>
                      <td rowspan="1" colspan="1">14 (93.3%)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Post-secondary education</td>
                      <td rowspan="1" colspan="1">0 (0%)</td>
                      <td rowspan="1" colspan="1">0 (0%)</td>
                      <td rowspan="1" colspan="1">1 (6.7%)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td colspan="5" rowspan="1">Sexual risk behavior in the last 3 months, n (%)</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> &gt;1 partner</td>
                      <td rowspan="1" colspan="1">2 (8.7%)</td>
                      <td rowspan="1" colspan="1">4 (20%)</td>
                      <td rowspan="1" colspan="1">1 (6.7%)</td>
                      <td rowspan="1" colspan="1">0.46</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> 1 partner</td>
                      <td rowspan="1" colspan="1">21 (91.3%)</td>
                      <td rowspan="1" colspan="1">16 (80%)</td>
                      <td rowspan="1" colspan="1">14 (93.3%)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> New partner</td>
                      <td rowspan="1" colspan="1">0 (0%)</td>
                      <td rowspan="1" colspan="1">4 (20%)</td>
                      <td rowspan="1" colspan="1">0 (0%)</td>
                      <td rowspan="1" colspan="1">0.01</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Condomless sex</td>
                      <td rowspan="1" colspan="1">19 (82.6%)</td>
                      <td rowspan="1" colspan="1">13 (65%)</td>
                      <td rowspan="1" colspan="1">9 (60%)</td>
                      <td rowspan="1" colspan="1">0.31</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Condom use (always)</td>
                      <td rowspan="1" colspan="1">4 (17.4%)</td>
                      <td rowspan="1" colspan="1">7 (35%)</td>
                      <td rowspan="1" colspan="1">6 (40%)</td>
                      <td rowspan="1" colspan="1">0.14</td>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Condom use (often)</td>
                      <td rowspan="1" colspan="1">0 (0%)</td>
                      <td rowspan="1" colspan="1">0 (0%)</td>
                      <td rowspan="1" colspan="1">1 (6.7%)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Condom use (sometimes)</td>
                      <td rowspan="1" colspan="1">13 (56.5%)</td>
                      <td rowspan="1" colspan="1">11 (55%)</td>
                      <td rowspan="1" colspan="1">8 (53.3%)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td rowspan="1" colspan="1"> Condom use (never)</td>
                      <td rowspan="1" colspan="1">6 (26.1%)</td>
                      <td rowspan="1" colspan="1">2 (10%)</td>
                      <td rowspan="1" colspan="1">0 (0%)</td>
                      <td rowspan="1" colspan="1"/>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <fn id="ciac284-tblfn1">
                    <p>Abbreviations: BMI, body mass index; Cu-IUD, copper T intrauterine device; DMPA-IM,
intramuscular depot medroxyprogesterone acetate; LNG, 2-rod levonorgestrel.</p>
                  </fn>
                  <fn id="ciac284-tblfn2">
                    <label>a</label>
                    <p>Values are median and interquartile range.</p>
                  </fn>
                  <fn id="ciac284-tblfn3">
                    <label>b</label>
                    <p>By Nugent scoring: score of 0–3 is negative, score of 4–6 is intermediate, score of
7–10 is positive.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>We studied cervical CD4+ T cells before and after contraceptive initiation using flow
cytometry. The gating strategy is shown in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 1</xref>. At baseline, the frequency of CD4+ T cells was
similar across study arms (<xref rid="sup1" ref-type="supplementary-material">Supplementary
Figure 2</xref><italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">A</xref></italic>), and contraception did not alter this (<xref rid="ciac284-F1" ref-type="fig">Figure 1</xref><italic toggle="yes"><xref rid="ciac284-F1" ref-type="fig">A</xref></italic> and <xref rid="ciac284-F1" ref-type="fig">1</xref><italic toggle="yes"><xref rid="ciac284-F1" ref-type="fig">B</xref></italic>). However, DMPA-IM use was associated
with a reduced frequency of CD4+ HLA-DR+ T cells compared with baseline (<italic toggle="yes">P</italic>
= .008) and with Cu-IUD (<italic toggle="yes">P</italic> = .002; <xref rid="ciac284-F1" ref-type="fig">Figure 1</xref><italic toggle="yes"><xref rid="ciac284-F1" ref-type="fig">C</xref></italic>).
Contraceptives did not alter CCR5 (<xref rid="ciac284-F1" ref-type="fig">Figure
1</xref><italic toggle="yes"><xref rid="ciac284-F1" ref-type="fig">D</xref></italic>) or α4β7 (<xref rid="ciac284-F1" ref-type="fig">Figure 1</xref><italic toggle="yes"><xref rid="ciac284-F1" ref-type="fig">E</xref></italic>) expression.</p>
              <fig position="float" id="ciac284-F1" fig-type="figure">
                <label>Figure 1.</label>
                <caption>
                  <p>Frequencies of cervical CD4+ T cells in women randomized to the Cu-IUD (n = 23; red),
DMPA-IM (n = 20; blue), or LNG implant (n = 15; green) at baseline and 1 month after
initiating contraception. Graphs show the differences pre-post contraceptive initiation
for the frequencies of cervical (<italic toggle="yes">A</italic>) CD4+ T cells, (<italic toggle="yes">B</italic>)
CD38+ CD4+ T cells, (<italic toggle="yes">C</italic>) HLA-DR+ CD4+ T cells, (<italic toggle="yes">D</italic>)
CCR5+ CD4+ T cells, and (<italic toggle="yes">E</italic>) α4β7+ CD4+ T cells. The horizontal bars
indicate the median. Statistical comparisons were performed using the Wilcoxon
matched-pairs tests for matched data or the Kruskal-Wallis test with false discovery
rate correction for cross-sectional data. Abbreviations: Cu-IUD, copper T intrauterine
device; DMPA-IM, intramuscular depot medroxyprogesterone acetate; LNG, 2-rod
levonorgestrel.</p>
                </caption>
                <graphic xlink:href="ciac284f1" position="float"/>
              </fig>
              <p>We next examined the impact of contraceptives on Th17-like HIV target cells, identified by
expression of CCR6 and CCR10 (CCR6+ CCR10−) [<xref rid="ciac284-B20" ref-type="bibr">20–22</xref>]. There were no differences in the frequency of cervical
Th17-like cells between contraceptive arms at baseline (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 2</xref><italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">B</xref></italic>). Of note, only the
initiation of DMPA-IM resulted in a significant increase in the frequency of Th17-like
cells, compared with baseline (<italic toggle="yes">P</italic> = .012; median change, 12.8%; <xref rid="ciac284-F2" ref-type="fig">Figure 2</xref><italic toggle="yes"><xref rid="ciac284-F2" ref-type="fig">A</xref></italic>). At 1 month, women using DMPA-IM had 1.7-fold higher
frequencies of Th17-like cells compared with women using the Cu-IUD (<italic toggle="yes">P</italic> =
.0002) and 1.2-fold more than women using an LNG implant (<italic toggle="yes">P</italic> = .04; <xref rid="ciac284-F2" ref-type="fig">Figure 2</xref><italic toggle="yes"><xref rid="ciac284-F2" ref-type="fig">B</xref></italic>). Furthermore, DMPA-IM induced a significant increase
in the frequency of activated, CD38+ Th17-like cells compared with baseline
(<italic toggle="yes">P</italic> = .044; median difference, 9.2%; <xref rid="ciac284-F2" ref-type="fig">Figure 2</xref><italic toggle="yes"><xref rid="ciac284-F2" ref-type="fig">C</xref></italic>), such
that women using DMPA-IM had significantly higher frequencies of activated Th17-like cells
compared with Cu-IUD (<italic toggle="yes">P</italic> = .026; median, 32.6%) but not the LNG implant
(<italic toggle="yes">P</italic> = .215; median, 39.3%) at 1 month (<xref rid="ciac284-F2" ref-type="fig">Figure 2</xref><italic toggle="yes"><xref rid="ciac284-F2" ref-type="fig">D</xref></italic>). DMPA-IM use was also associated with a decrease in the frequency of
HLA-DR+ Th17-like cells (<italic toggle="yes">P</italic> = .004; median difference, −4.2%; <xref rid="ciac284-F2" ref-type="fig">Figure 2</xref><italic toggle="yes"><xref rid="ciac284-F2" ref-type="fig">E</xref></italic>), although the levels of these cells at 1 month was
similar across study arms (medians: 10.4%, 8.28%, and 9.18% for Cu-IUD, DMPA-IM, and LNG
implant, respectively; <xref rid="ciac284-F2" ref-type="fig">Figure 2</xref><italic toggle="yes"><xref rid="ciac284-F2" ref-type="fig">F</xref></italic>). The activation profile of Th17-like
cells was significantly skewed 1 month after DMPA-IM initiation compared with baseline
(<italic toggle="yes">P</italic> = .044), and this was also significantly different compared with the
Cu-IUD (<italic toggle="yes">P</italic> = .024; <xref rid="ciac284-F2" ref-type="fig">Figure
2</xref><italic toggle="yes"><xref rid="ciac284-F2" ref-type="fig">G</xref></italic>).</p>
              <fig position="float" id="ciac284-F2" fig-type="figure">
                <label>Figure 2.</label>
                <caption>
                  <p>The frequency of activated Th17 HIV target cells in women randomized to the Cu-IUD (n =
23; red), DMPA-IM (n = 20; blue), or LNG implant (n = 15; green). (<italic toggle="yes">A</italic>)
The frequency of Th17-like cells (CCR6+ CCR10–) before and after initiation of
contraception. (<italic toggle="yes">B</italic>) The cross-sectional comparison of Th17 frequency
post-contraceptive initiation across study arms. (<italic toggle="yes">C</italic>) The frequency of
CD38+ Th17 cells before and after initiation of contraception. (<italic toggle="yes">D</italic>) The
cross-sectional comparison of CD38+ Th17 frequency post-contraceptive initiation across
study arms. (<italic toggle="yes">E</italic>) The frequency of HLA-DR+ Th17 cells before and after
initiation of contraception. (<italic toggle="yes">F</italic>) The cross-sectional comparison of
HLA-DR+ Th17 frequency post-contraceptive initiation across study arms. The horizontal
bars indicate the median. (<italic toggle="yes">G</italic>) Proportions of activated Th17 cells
expressing different combinations of CD38 and HLA-DR. Statistical comparisons were
performed using the Wilcoxon matched-pairs tests for matched data or the Kruskal-Wallis
with false discovery rate correction for cross-sectional comparisons. Abbreviations:
Cu-IUD, copper T intrauterine device; DMPA-IM, intramuscular depot medroxyprogesterone
acetate; HIV, human immunodeficiency virus; LNG, 2-rod levonorgestrel; Th17, T-helper
17.</p>
                </caption>
                <graphic xlink:href="ciac284f2" position="float"/>
              </fig>
              <p>Next, the expression of the HIV co-receptors CCR5 and α4β7 was measured. Generally, CCR5
was expressed on the majority of cervical Th17-like cells (median, 74%; IQR, 63.75–86.5%;
<xref rid="ciac284-F3" ref-type="fig">Figure 3</xref><italic toggle="yes"><xref rid="ciac284-F3" ref-type="fig">A</xref></italic>), with no differences at baseline (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 2</xref><italic toggle="yes"><xref rid="sup1" ref-type="supplementary-material">B</xref></italic>). Neither DMPA-IM nor the
LNG implant induced changes in the frequency of CCR5+ Th17-like cells (<xref rid="ciac284-F3" ref-type="fig">Figure 3</xref><italic toggle="yes"><xref rid="ciac284-F3" ref-type="fig">A</xref></italic>). However, women using the Cu-IUD had a substantial
decrease in the frequency of CCR5+ Th17-like cells compared with baseline
(<italic toggle="yes">P</italic> = .038; median difference, −13.3%). Nonetheless, there were no
differences in the frequency of CCR5+ Th17-like cells between study arms after 1 month of
contraceptive use (<xref rid="ciac284-F3" ref-type="fig">Figure 3</xref><italic toggle="yes"><xref rid="ciac284-F3" ref-type="fig">B</xref></italic>). The density of CCR5 per cell
(measured by the median fluorescent intensity [MFI]) was significantly increased in women
using the Cu-IUD (<italic toggle="yes">P</italic> = .004; median difference, 800 units; <xref rid="ciac284-F3" ref-type="fig">Figure 3</xref><italic toggle="yes"><xref rid="ciac284-F3" ref-type="fig">C</xref></italic>), suggesting there are fewer CCR5+ cells for HIV to
infect, but these may be more susceptible to HIV on an individual cell basis. Despite this,
the MFI of CCR5 was similar between contraceptive arms post-initiation (<xref rid="ciac284-F3" ref-type="fig">Figure 3</xref><italic toggle="yes"><xref rid="ciac284-F3" ref-type="fig">D</xref></italic>). Unlike CCR5, fewer than one-quarter of cervical
Th17-like cells expressed α4β7 (median, 22.3%; IQR, 15.15–35%; <xref rid="ciac284-F3" ref-type="fig">Figure 3</xref><italic toggle="yes"><xref rid="ciac284-F3" ref-type="fig">E</xref></italic>). Although not statistically significant, 12 of 58 women (n = 5, n = 5,
and n = 2 in DMPA-IM, LNG-implant, or CU-IUD arms, respectively) had an approximately 3-fold
increase in the frequency of α4β7, with post-contraceptive expression exceeding 75% in 6 of
12 of these women. There were no differences in α4β7+ Th17-like cells between study arms at
1 month (<xref rid="ciac284-F3" ref-type="fig">Figure 3</xref><italic toggle="yes"><xref rid="ciac284-F3" ref-type="fig">F</xref></italic>), and none of the contraceptives induced MFI changes
(<xref rid="ciac284-F3" ref-type="fig">Figure 3</xref><italic toggle="yes"><xref rid="ciac284-F3" ref-type="fig">G</xref></italic> and <xref rid="ciac284-F3" ref-type="fig">3</xref><italic toggle="yes"><xref rid="ciac284-F3" ref-type="fig">H</xref></italic>). Thus, DMPA-IM
use was associated with an increase in activated Th17-like cells, but unexpectedly had
little effect on the overall expression of HIV co-receptors [<xref rid="ciac284-B11" ref-type="bibr">11</xref>, <xref rid="ciac284-B23" ref-type="bibr">23</xref>].</p>
              <fig position="float" id="ciac284-F3" fig-type="figure">
                <label>Figure 3.</label>
                <caption>
                  <p>The expression of HIV receptors CCR5 and α4β7 on Th17 target cells in women randomized
to the Cu-IUD (n = 23; red), DMPA-IM (n = 20; blue), or LNG implant (n = 15; green).
(<italic toggle="yes">A</italic>) The frequency of CCR5+ Th17 before and after initiation of
contraception. (<italic toggle="yes">B</italic>) The cross-sectional comparison of CCR5+ Th17
frequency post-contraceptive initiation across study arms. (<italic toggle="yes">C</italic>) The MFI
of CCR5 on Th17 cells before and after initiation of contraception. (<italic toggle="yes">D</italic>)
The cross-sectional comparison of CCR5 MFI post-contraceptive initiation across study
arms. (<italic toggle="yes">E</italic>) The frequency of α4β7+ Th17 cells before and after initiation
of contraception. (<italic toggle="yes">F</italic>) The cross-sectional comparison of α4β7+ Th17
frequency post-contraceptive initiation across study arms. (<italic toggle="yes">G</italic>) The MFI
of α4β7 on Th17 cells before and after initiation of contraception. (<italic toggle="yes">H</italic>)
The cross-sectional comparison of α4β7 MFI post-contraceptive initiation across study
arms. Th17 cells were defined as CD4+ CCR6+ CCR10−. The horizontal bars indicate the
median. Statistical comparisons were performed using the Wilcoxon matched-pairs tests
for matched data or the Kruskal-Wallis with false discovery rate correction for
cross-sectional comparisons. Abbreviations: Cu-IUD, copper T intrauterine device;
DMPA-IM, intramuscular depot medroxyprogesterone acetate; LNG, 2-rod levonorgestrel;
MRI, median fluorescent intensity; Th17, T-helper 17.</p>
                </caption>
                <graphic xlink:href="ciac284f3" position="float"/>
              </fig>
              <p>Since HIV entry into cells may depend on the co-expression of cell-surface markers [<xref rid="ciac284-B6" ref-type="bibr">6</xref>], we assessed co-expression of these markers
across study arms. Overall, Th17-like cells expressing CCR5 alone were the most highly
abundant, irrespective of study arm or time point (median, 28.5%; IQR, 17.73–39.01%; <xref rid="ciac284-F4" ref-type="fig">Figure 4</xref>). Compared with baseline, only DMPA-IM
initiation resulted in an increased frequency of CD38+ CCR5+ α4β7+ Th17-like cells, a
population likely to be highly HIV susceptible (<italic toggle="yes">P</italic> = .003), while both the
Cu-IUD and LNG implant induced decreases in other Th17-like populations (<xref rid="ciac284-F4" ref-type="fig">Figure 4</xref><italic toggle="yes"><xref rid="ciac284-F4" ref-type="fig">A</xref></italic>). We next compared the most abundant subsets (median
frequency &gt;5%) between contraceptive arms at 1 month (<xref rid="ciac284-F4" ref-type="fig">Figure 4</xref><italic toggle="yes"><xref rid="ciac284-F4" ref-type="fig">B</xref></italic>). The frequency of CD38+ CCR5+ α4β7+ Th17-like cells was higher in
women using progestin-only contraceptives compared with those using the Cu-IUD (DMPA-IM
[median, 10.05%] vs Cu-IUD [median, 3.9%]; <italic toggle="yes">P</italic> = .005; and LNG implant
[median, 9.82%] vs Cu-IUD; <italic toggle="yes">P</italic> = .014; <xref rid="ciac284-F4" ref-type="fig">Figure 4</xref><italic toggle="yes"><xref rid="ciac284-F4" ref-type="fig">B</xref></italic>) but
similar between DMPA-IM and LNG implant (<italic toggle="yes">P</italic> = .247). Therefore, DMPA-IM
initiation led to a significant increase in susceptible Th17-like cells from baseline and,
in comparison, to women using Cu-IUD.</p>
              <fig position="float" id="ciac284-F4" fig-type="figure">
                <label>Figure 4.</label>
                <caption>
                  <p>Changes in the co-expression of HIV target cell markers on Th17 cells from women
randomized to the Cu-IUD (n = 23; red), DMPA-IM (n = 20; blue), or LNG implant (n = 15;
green). The cross-sectional comparison of Th17 populations expressing CD38, HLA-DR,
α4β7, and CCR5 in different combinations: (<italic toggle="yes">A</italic>) before and after the
start of contraception and (<italic toggle="yes">B</italic>) between study arms post-contraceptive
initiation with the 5 most abundant populations (medians &gt;5% for at least 1
contraceptive arm at either time point). The dashed line indicates the 5% cutoff. Th17
cells were defined as CD4+ CCR6+ CCR10−. Statistical comparisons were performed using
the Wilcoxon matched-pairs tests for matched data or the Kruskal-Wallis with false
discovery rate correction for cross-sectional comparisons. Abbreviations: Cu-IUD, copper
T intrauterine device; DMPA-IM, intramuscular depot medroxyprogesterone acetate; HIV,
human immunodeficiency virus; LNG, 2-rod levonorgestrel; Th17, T-helper 17.</p>
                </caption>
                <graphic xlink:href="ciac284f4" position="float"/>
              </fig>
              <p>The vaginal microbiome may also influence HIV susceptibility, and since Th17 cells mediate
antibacterial immunity, we next evaluated whether the vaginal microbiome influenced the
abundance of Th17-like cells in the context of contraceptive use. Using available sequencing
data (n = 47), 5 CSTs were identified at baseline, with no clear separation by contraceptive
arm (<xref rid="ciac284-F5" ref-type="fig">Figure 5</xref><italic toggle="yes"><xref rid="ciac284-F5" ref-type="fig">A</xref></italic>). Overall, CSTs III-A, and IV-D were the most common,
comprising 27.7% and 29.8% of women, respectively. Women were grouped according to whether
they had baseline <italic toggle="yes">Lactobacillus</italic> spp.<italic toggle="yes">–</italic>dominant microbiota
(CSTs III-A or I-B) or not (CSTs IV-A, IV-B, or IV-D). Only 15 of 47 women (32%) had a
<italic toggle="yes">Lactobacillus-</italic>dominant (LD) microbiome at baseline, with nearly half of
them randomized to DMPA-IM (7/15; 46%). Cervical Th17-like cell frequencies were similar
between baseline and 1 month in women with an LD vaginal microbiome and those without (<xref rid="ciac284-F5" ref-type="fig">Figure 5</xref><italic toggle="yes"><xref rid="ciac284-F5" ref-type="fig">B</xref></italic>). Interestingly, the initiation of DMPA-IM resulted in
an increase in Th17-like cell abundance in women with non-LD microbiomes (<italic toggle="yes">P</italic>
= .03) but not in women with LD microbiomes. Women using DMPA-IM also had higher frequencies
of Th17-like cells at 1 month, compared with those using the Cu-IUD (<xref rid="ciac284-F5" ref-type="fig">Figure 5</xref><italic toggle="yes"><xref rid="ciac284-F5" ref-type="fig">C</xref></italic>), in both the LD (<italic toggle="yes">P</italic> = .025) and non-LD groups
(<italic toggle="yes">P</italic> = .008). Similarly, women with non-LD microbiomes using DMPA-IM had
elevated Th17-like cells compared with those using the LNG implant (<italic toggle="yes">P</italic> =
.043), but not in the subgroup of LD women. Finally, the microbiome at baseline or after 4
weeks of contraceptive use was not associated with Th17-like cell abundance post–DMPA-IM
(<xref rid="ciac284-F5" ref-type="fig">Figure 5</xref><italic toggle="yes"><xref rid="ciac284-F5" ref-type="fig">D</xref></italic>). These data suggest that the microbiome could play a
role in the contraceptive-induced accumulation of Th17-like cells and should be investigated
further.</p>
              <fig position="float" id="ciac284-F5" fig-type="figure">
                <label>Figure 5.</label>
                <caption>
                  <p>The effect of the vaginal microbiome at baseline on the abundance of Th17-like cells in
women randomized to the Cu-IUD (n = 17; red), DMPA-IM (n = 17; blue), or LNG implant (n
= 13; green). (<italic toggle="yes">A</italic>) Relative abundance of the different vaginal bacterial
species in each participant at baseline, where data were available (n = 47). The CSTs
are shown above the panel. The color of the dots at the bottom of the panel indicates
which contraceptive arm the participant was randomized to (red for CU-IUD, blue for
DMPA-IM, and green for LNG implant). (<italic toggle="yes">B</italic>) Th17 cell frequency before and
after initiation of contraception in women with a
<italic toggle="yes">Lactobacillus-</italic>dominant (CSTs III-A or I-B; n = 15) or
non–<italic toggle="yes">Lactobacillus-</italic>dominant microbiome (CSTs IV-A, IV-B, or IV-D; n =
32). Statistical comparisons were performed using the Wilcoxon matched-pairs tests.
(<italic toggle="yes">C</italic>) The cross-sectional comparison of Th17 frequency
post-contraceptive initiation across study arms in women with a
<italic toggle="yes">Lactobacillus-</italic>dominant or non–<italic toggle="yes">Lactobacillus-</italic>dominant
microbiome. Statistical comparisons were performed using Kruskal–Wallis with false
discovery rate correction. (<italic toggle="yes">D</italic>) Linear associations between women with
<italic toggle="yes">Lactobacillus-</italic>dominant microbiomes at baseline (pre) and at month 1
post–DMPA-IM (post) and Th17-like cell abundance post–DMPA-IM initiation. The
associations are shown as a β-coefficient with error bars representing the 95%
confidence interval. Abbreviations: CST, community state type; Cu-IUD, copper T
intrauterine device; DMPA-IM, intramuscular depot medroxyprogesterone acetate; HIV,
human immunodeficiency virus; LNG, 2-rod levonorgestrel; Th17, T-helper 17.</p>
                </caption>
                <graphic xlink:href="ciac284f5" position="float"/>
              </fig>
              <p>To better understand potential pathways accompanying elevated Th17-like cells in women
using DMPA-IM, we interrogated cervicovaginal proteome signatures related to Th17-like
cells. We identified 634 proteins by mass spectrometry in samples collected at baseline and
post–DMPA-IM initiation. Of these, 87 of 634 (13.7%) proteins were significantly correlated
with increased Th17-like cells post–DMPA initiation. Pathway analysis proteins negatively
associated with Th17-like cell numbers included inflammatory pathways, including the acute
phase response, the liver X receptor (LXR)/retinoid receptor (RXR) activation, and movement
of neutrophils (<italic toggle="yes">P</italic> &lt; .001; <xref rid="ciac284-F6" ref-type="fig">Figure
6</xref><italic toggle="yes"><xref rid="ciac284-F6" ref-type="fig">A</xref></italic>). In contrast,
increases in Th17-like cells positively correlated with proteins involved in mucosal barrier
integrity, including epithelial cell–cell adhesion junction proteins (<italic toggle="yes">P</italic>
&lt; .0001), protease inhibition (<italic toggle="yes">P</italic> &lt; .0001), actin cytoskeletal
components (<italic toggle="yes">P</italic> = .0006), and cell-matrix adhesion (<italic toggle="yes">P</italic> =
.0094; <xref rid="ciac284-F6" ref-type="fig">Figure 6</xref><italic toggle="yes"><xref rid="ciac284-F6" ref-type="fig">A</xref></italic>). Hierarchical clustering showed a well-defined
association between increased abundance of Th17 cells with tight junction and structural
proteins, while antiproteases, known to play a role in wound healing and tissue maintenance,
were found to decrease (<xref rid="ciac284-F6" ref-type="fig">Figure 6</xref><italic toggle="yes"><xref rid="ciac284-F6" ref-type="fig">B</xref></italic>). Although the microbiome did not
significantly impact Th17-associated proteins in women using DMPA-IM, an LD microbiome was
more prevalent with increased Th17-associated proteins involved in cell–cell adhesion (<xref rid="sup1" ref-type="supplementary-material">Supplementary Figure 3</xref>), suggesting a
relationship between mucosal barrier disruption, Th17 cells, and the microbiome. Overall,
our important findings suggest that Th17-like cells in the genital tract maintain mucosal
barrier function in the context of DMPA-IM use. Thus, any increased risk of HIV infection in
women using DMPA-IM due to increased HIV target cell availability is likely abrogated by the
same Th17-like cells promoting mucosal barrier integrity.</p>
              <fig position="float" id="ciac284-F6" fig-type="figure">
                <label>Figure 6.</label>
                <caption>
                  <p>Proteome signatures associated with Th17 cell levels in women randomized to DMPA-IM.
Cervicovaginal samples taken at baseline and post–DMPA-IM initiation (n = 20) were
analyzed by label-free mass spectrometry. Longitudinal differences in Th17-like cells
and proteins were correlated using Pearson’s <italic toggle="yes">R</italic> test, which found 13.7%
of proteins to be significantly correlated (<italic toggle="yes">P</italic> = .05).
(<italic toggle="yes">A</italic>) Pathway annotation using IPA and DAVID bioinformatics identified
5 unique biological pathways increased and 6 decreased with the increase in Th17-like
cells. (<italic toggle="yes">B</italic>) Hierarchical clustering showing the associations between the
increase in Th17 cells and corresponding increase in mucosal barrier integrity proteins.
Abbreviations: DMPA-IM, intramuscular depot medroxyprogesterone acetate; Th17, T-helper
17.</p>
                </caption>
                <graphic xlink:href="ciac284f6" position="float"/>
              </fig>
            </sec>
            <sec sec-type="discussion" id="ciac284-s3">
              <title>DISCUSSION</title>
              <p>Mucosal Th17 cells make efficient HIV targets [<xref rid="ciac284-B8" ref-type="bibr">8</xref>, <xref rid="ciac284-B24" ref-type="bibr">24</xref>, <xref rid="ciac284-B25" ref-type="bibr">25</xref>], evidenced by their profound depletion in early infection
[<xref rid="ciac284-B20" ref-type="bibr">20</xref>, <xref rid="ciac284-B26" ref-type="bibr">26</xref>]. We compared the consequences of contraceptives on local HIV
target cells in the ECHO study, the only randomized contraceptive trial conducted to
date.</p>
              <p>DMPA-IM had the most pronounced effect on cervical Th17-like cells. Women assigned to
DMPA-IM had significantly increased frequencies of Th17-like cells compared with baseline
and compared with women assigned to Cu-IUD or LNG implant after 1 month. We also observed an
increase in an activated, HIV-susceptible Th17-like cell population co-expressing CCR5 and
α4β7 (CD38+ CCR5+ α4β7+) after 1 month of DMPA-IM use. However, there was no increased
activation or abundance in the total CD4+ T-cell population, consistent with some previous
findings [<xref rid="ciac284-B23" ref-type="bibr">23</xref>] and highlighting the need for
deeper examination of susceptible subsets.</p>
              <p>We initially hypothesized that women using DMPA-IM would experience higher HIV incidence
rates related to an increased abundance or activation of cervical Th17-like cells [<xref rid="ciac284-B3" ref-type="bibr">3</xref>, <xref rid="ciac284-B26" ref-type="bibr">26–28</xref>]. Although we could not directly measure associations between
Th17-like cells and HIV acquisition, the ECHO trial reported no increased risk of HIV in
DMPA-IM users compared with others. However, we still observed an increased abundance of
cervical Th17-like cells post–DMPA-IM initiation, in direct contrast to the prediction that
increased HIV target cell infiltration would translate to higher HIV risk.</p>
              <p>Our key finding was the Th17-associated increase in mucosal barrier proteins in women using
DMPA-IM. Although we ascribe Th17 cells to the role of HIV target cells, their primary role
is in maintenance of barrier integrity [<xref rid="ciac284-B12" ref-type="bibr">12</xref>,
<xref rid="ciac284-B13" ref-type="bibr">13</xref>]. Our data suggest that the
DMPA-IM–driven accumulation of HIV-susceptible Th17-like cells might be counteracted by
their role in maintaining the epithelial barrier of the female genital tract. Previously,
DMPA-IM has been associated with compromised barrier function, including a reduction in
epithelial repair proteins, which may be a mechanism by which HIV risk is increased [<xref rid="ciac284-B29" ref-type="bibr">29</xref>, <xref rid="ciac284-B30" ref-type="bibr">30</xref>]. Consequently, our data showing maintained mucosal barrier function are in
agreement with the lack of greater HIV incidence in women using DMPA-IM in the ECHO trial.
We found no link between the microbiome and Th17-associated mucosal barrier proteins,
although others have reported detrimental changes in barrier function–associated protein
signatures during dysbiosis [<xref rid="ciac284-B31" ref-type="bibr">31</xref>].</p>
              <p>Previous reports suggest that DMPA-IM impacts Th17 cells by influencing the vaginal
microbiome [<xref rid="ciac284-B32" ref-type="bibr">32</xref>]. Here, women with non-LD
microbiomes at baseline had more Th17-like cells post–DMPA-IM. However, the sample size for
our analysis was small, and these data need to be interpreted cautiously. Studies also show
that women with moderate dysbiosis using hormonal contraception had mucosal barrier protein
profiles similar to women with LD microbiomes [<xref rid="ciac284-B31" ref-type="bibr">31</xref>]. Based on our findings, we may consider that hormonal contraception may
promote mucosal barrier function through the accumulation of Th17-like cells, despite
vaginal dysbiosis.</p>
              <p>The differences in Th17-like cell abundance between contraceptives may reflect differences
in pharmacodynamic properties [<xref rid="ciac284-B3" ref-type="bibr">3</xref>]. Indeed, the
increase in Th17-like cells post–DMPA-IM coincides with peak concentrations of
medroxyprogesterone acetate (MPA), suggesting a transient effect [<xref rid="ciac284-B3" ref-type="bibr">3</xref>, <xref rid="ciac284-B33" ref-type="bibr">33</xref>, <xref rid="ciac284-B34" ref-type="bibr">34</xref>], which may be too short-lived to
substantially increase HIV risk [<xref rid="ciac284-B32" ref-type="bibr">32</xref>, <xref rid="ciac284-B35" ref-type="bibr">35</xref>]. In line with our proteomic analyses,
Th17-like cells may also be accumulating in response to transient MPA-induced epithelial
thinning [<xref rid="ciac284-B29" ref-type="bibr">29</xref>, <xref rid="ciac284-B36" ref-type="bibr">36</xref>, <xref rid="ciac284-B37" ref-type="bibr">37</xref>]. Th17-like
cells may return to baseline levels once MPA concentrations plateau.</p>
              <p>Our findings have implications for the use of cervical Th17-like cells as a proxy for HIV
risk. If we consider a minimum threshold of target cells required to impact HIV acquisition
risk, the sampling method used to collect cervical cells is particularly relevant.
Cytobrushes collect relatively superficial cervical intraepithelial cells, which are easily
accessible to luminal HIV. However, the abundance of cervical cells is unlikely to
correspond to that of vaginal, endometrial, or submucosal HIV-susceptible cells, which have
the potential to be infected, either by cell migration or contact with HIV in the instance
of reduced barrier function [<xref rid="ciac284-B38" ref-type="bibr">38</xref>, <xref rid="ciac284-B39" ref-type="bibr">39</xref>].</p>
              <p>In conclusion, we report an increase in the abundance of highly susceptible, cervical
Th17-like HIV target cells in women using DMPA-IM, evident within 1 month of initiation.
Importantly, proteomic signatures related to enhanced mucosal barrier function corresponded
to the abundance of Th17-like cells in these women. Thus, the DMPA-IM–driven accumulation of
HIV-susceptible Th17-like cells might be counteracted by their role in maintaining mucosal
barrier integrity.</p>
            </sec>
            <sec sec-type="supplementary-material" id="ciac284-s4">
              <title>Supplementary Data</title>
              <p><xref rid="sup1" ref-type="supplementary-material">Supplementary materials</xref> are
available at <italic toggle="yes">Clinical Infectious Diseases</italic> online. Consisting of data
provided by the authors to benefit the reader, the posted materials are not copyedited and
are the sole responsibility of the authors, so questions or comments should be addressed to
the corresponding author.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <supplementary-material id="sup1" position="float" content-type="local-data">
                <label>ciac284_Supplementary_Data</label>
                <media xlink:href="ciac284_supplementary_data.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <sec id="ciac284-n1">
              <title>Notes</title>
              <p><bold><italic toggle="yes">Author contributions</italic>.</bold> Conceived and designed the study: J.-A. S.
P, H. J., R. Heffron, S. E. B., A. B., and R. B. Cohort management and sample collection: G.
N., M. O., T. P.-P., C. S., K. B. H., J. M. B, H. J., and R. Heffron. Performed the
experiments: R. B., T. F. R, S. Z. J., H. G., R. Harryprasad, B. P. B., L. N.-R., and H.A.
Analyzed the data: R. B., T. F. R, S. D., K. B. H, B. P. B., L. N.-R., and H. A. Wrote the
manuscript: R. B., B. P. B., L. N.-R., H. A., J.-A. S. P, H. J., and R. Heffron.</p>
              <p><bold><italic toggle="yes">Acknowledgments.</italic></bold> The authors thank all the women who participated in this study for their devotion to
the study and the time they committed to research procedures.</p>
              <p><bold><italic toggle="yes">Financial support.</italic></bold> The work was supported by the Bill &amp; Melinda Gates Foundation, US Agency for
International Development, and the President’s Emergency Plan for AIDS Relief, Swedish
International Development Cooperation Agency (SIDA), South African Medical Research Council,
and UN Population Fund. Contraceptive supplies were donated by the Government of South
Africa and US Agency for International Development. This study was also funded by the US
National Institute of Child Health and Human Development. J.-A. S. P., A. B., and B. P. B.
report support for this work from the National Institutes of Health R01 (R01HD089831-05;
Effects of hormonal contraceptives on genital immunity and HIV susceptibility). J.-A. S. P.
also reports support from the ECHO Biological Mechanisms Ancillary Study (principal
investigators: Dr Heather Jaspan and Dr Renee Heffron; co-investigators: Dr Jo-Ann
Passmore). B. P. B. also reports additional support for this work from the National
Institutes of Health (NIH F32HD102290).</p>
              <p><bold><italic toggle="yes">R01HD089831 ECHO Biological Mechanisms Ancillary Study Team.</italic></bold> Members of the R01HD089831 ECHO Biological Mechanisms Ancillary Study Team include
the following—Coordinating center (University of Washington): Renee Heffron, Heather Jaspan
(principal investigators); Jared Baeten, Caitlin Scoville, Kate Heller, Harald Haugen, Colin
Pappajohn. Study sites: Emavundleni Research Centre–University of Cape Town, Desmond Tutu
HIV Centre (Cape Town, South Africa): Gonasagrie Nair (principal investigator), Banzi Bam,
Elaine Sebastian, Ebrahiema Jacobs. Kenya Medical Research Institute–Research Care and
Training Program (Kisumu, Kenya): Maricianah Onono (principal investigator), Lizzie Kabete,
Imeldah Wakhungu. Wits Reproductive Health and HIV Institute, University of Witswatersrand
(Johannesburg, South Africa): Thesla Palanee-Phillips (principal investigator), Krishnaveni
Reddy, Emily Kekana, Cecelia Mokoena, Nomsa Morudu, Kerushini Moodley. Laboratories: Center
for Global Health and Diseases, Case Western Reserve University (Cleveland, OH, USA): Adam
Burgener (principal investigator). Emory University (Atlanta, GA, USA): Steven Bosinger
(principal investigator), Prachi Gupta, Sydney Nelson. Seattle Children’s Research Institute
(Seattle, WA, USA): Heather Jaspan (principal investigator), Bryan Brown. University of Cape
Town (Cape Town, South Africa): Jo-Ann Passmore (principal investigator), Heather Jaspan,
Shameem Jaumdally, Hoyam Gamieldien, Rubina Bunjun, Tanko Fatime Ramla, Anna-Ursula Happel,
Kathryn Norman, Rushil Harryparsad, Yamkela Qumbelo, Trishana Nundalall, Denzhe Singo, and
Vernon Plaatjies. University of Manitoba (Manitoba, Canada): Adam Burgener (principal
investigator), Laura Noel-Romas, Hossaena Ayele, Kenzie Birse, Samantha Hornes.</p>
            </sec>
            <ref-list id="ref1">
              <title>References</title>
              <ref id="ciac284-B1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>ECHO</collab></person-group>. <article-title>HIV incidence among women using intramuscular depot
medroxyprogesterone acetate, a copper intrauterine device, or a levonorgestrel implant
for contraception: a randomised, multicentre, open-label trial</article-title>.
<source>Lancet</source><year>2019</year>;
<volume>394</volume>:<fpage>303</fpage>–<lpage>13</lpage>.<pub-id pub-id-type="pmid">31204114</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Polis</surname><given-names>CB</given-names></string-name>, <string-name><surname>Curtis</surname><given-names>KM</given-names></string-name>, <string-name><surname>Hannaford</surname><given-names>PC</given-names></string-name>, <etal>et
al</etal></person-group><article-title>An updated systematic review of epidemiological evidence on hormonal
contraceptive methods and HIV acquisition in women</article-title>.
<source>AIDS</source><year>2016</year>;
<volume>30</volume>:<fpage>2665</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="pmid">27500670</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hapgood</surname><given-names>JP</given-names></string-name>, <string-name><surname>Kaushic</surname><given-names>C</given-names></string-name>, <string-name><surname>Hel</surname><given-names>Z</given-names></string-name></person-group>.
<article-title>Hormonal contraception and HIV-1 acquisition: biological
mechanisms</article-title>. <source>Endocr Rev</source><year>2018</year>;
<volume>39</volume>:<fpage>36</fpage>–<lpage>78</lpage>.<pub-id pub-id-type="pmid">29309550</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Heffron</surname><given-names>R</given-names></string-name>, <string-name><surname>Achilles</surname><given-names>SL</given-names></string-name>,
<string-name><surname>Dorflinger</surname><given-names>LJ</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Pharmacokinetic, biologic and epidemiologic differences in MPA- and
NET-based progestin-only injectable contraceptives relative to the potential impact on
HIV acquisition in women</article-title>.
<source>Contraception</source><year>2019</year>;
<volume>99</volume>:<fpage>199</fpage>–<lpage>204</lpage>.<pub-id pub-id-type="pmid">30576636</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mwatelah</surname><given-names>R</given-names></string-name>, <string-name><surname>McKinnon</surname><given-names>LR</given-names></string-name>,
<string-name><surname>Baxter</surname><given-names>C</given-names></string-name>, <string-name><surname>Abdool
Karim</surname><given-names>Q</given-names></string-name>, <string-name><surname>Abdool
Karim</surname><given-names>SS</given-names></string-name></person-group>.
<article-title>Mechanisms of sexually transmitted infection-induced inflammation in
women: implications for HIV risk</article-title>. <source>J Int AIDS
Soc</source><year>2019</year>;
<volume>22</volume>:<fpage>e25346</fpage>.<pub-id pub-id-type="pmid">31468677</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Joag</surname><given-names>VR</given-names></string-name>, <string-name><surname>McKinnon</surname><given-names>LR</given-names></string-name>,
<string-name><surname>Liu</surname><given-names>J</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Identification of preferential CD4+ T-cell targets for HIV infection in the
cervix</article-title>. <source>Mucosal Immunol</source><year>2015</year>;
<volume>9</volume>:<fpage>1</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">25872482</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Monteiro</surname><given-names>P</given-names></string-name>, <string-name><surname>Gosselin</surname><given-names>A</given-names></string-name>, <string-name><surname>Wacleche</surname><given-names>VS</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Memory CCR6<sup>+</sup> CD4<sup>+</sup> T cells are preferential targets
for productive HIV type 1 infection regardless of their expression of integrin
7</article-title>. <source>J Immunol</source><year>2011</year>;
<volume>186</volume>:<fpage>4618</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">21398606</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alvarez</surname><given-names>Y</given-names></string-name>, <string-name><surname>Tuen</surname><given-names>M</given-names></string-name>, <string-name><surname>Shen</surname><given-names>G</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Preferential HIV infection of CCR6<sup>+</sup> Th17 cells is associated
with higher levels of virus receptor expression and lack of CCR5
ligands</article-title>. <source>J Virol</source><year>2013</year>;
<volume>87</volume>:<fpage>10843</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">23903844</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cicala</surname><given-names>C</given-names></string-name>, <string-name><surname>Martinelli</surname><given-names>E</given-names></string-name>,
<string-name><surname>McNally</surname><given-names>JP</given-names></string-name>, <etal>et
al</etal></person-group><article-title>The integrin α<sub>4</sub>β<sub>7</sub> forms a complex with cell-surface
CD4 and defines a T-cell subset that is highly susceptible to infection by
HIV-1</article-title>. <source>Proc Natl Acad Sci USA</source><year>2009</year>;
<volume>106</volume>:<fpage>20877</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">19933330</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ding</surname><given-names>J</given-names></string-name>, <string-name><surname>Tasker</surname><given-names>C</given-names></string-name>, <string-name><surname>Lespinasse</surname><given-names>P</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Integrin α4β7 expression increases HIV susceptibility in activated cervical
CD4+ T cells by an HIV attachment-independent mechanism</article-title>. <source>J
Acquir Immune Defic Syndr</source><year>2015</year>;
<volume>69</volume>:<fpage>509</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="pmid">26167616</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Byrne</surname><given-names>EH</given-names></string-name>, <string-name><surname>Anahtar</surname><given-names>MN</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>KE</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Association between injectable progestin-only contraceptives and HIV
acquisition and HIV target cell frequency in the female genital tract in South African
women: a prospective cohort study</article-title>. <source>Lancet Infect
Dis</source><year>2016</year>;
<volume>16</volume>:<fpage>441</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">26723758</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Khader</surname><given-names>SA</given-names></string-name>, <string-name><surname>Gaffen</surname><given-names>SL</given-names></string-name>, <string-name><surname>Kolls</surname><given-names>JK</given-names></string-name></person-group>.
<article-title>Th17 cells at the crossroads of innate and adaptive immunity against
infectious diseases at the mucosa</article-title>. <source>Mucosal
Immunol</source><year>2009</year>;
<volume>2</volume>:<fpage>403</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">19587639</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bettelli</surname><given-names>E</given-names></string-name>, <string-name><surname>Korn</surname><given-names>T</given-names></string-name>, <string-name><surname>Oukka</surname><given-names>M</given-names></string-name>, <string-name><surname>Kuchroo</surname><given-names>VK</given-names></string-name></person-group>.
<article-title>Induction and effector functions of TH17 cells</article-title>.
<source>Nature</source><year>2008</year>;
<volume>453</volume>:<fpage>1051</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">18563156</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dabee</surname><given-names>S</given-names></string-name>, <string-name><surname>Barnabas</surname><given-names>SL</given-names></string-name>,
<string-name><surname>Lennard</surname><given-names>KS</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Defining characteristics of genital health in South African adolescent
girls and young women at high risk for HIV infection</article-title>. <source>PLoS
One</source><year>2019</year>;
<volume>14</volume>:<fpage>e0213975</fpage>.<pub-id pub-id-type="pmid">30947260</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Roederer</surname><given-names>M</given-names></string-name>, <string-name><surname>Nozzi</surname><given-names>JL</given-names></string-name>, <string-name><surname>Nason</surname><given-names>MC</given-names></string-name></person-group>.
<article-title>SPICE: exploration and analysis of post-cytometric complex multivariate
datasets</article-title>. <source>Cytometry A</source><year>2011</year>;
<volume>79</volume>:<fpage>167</fpage>–<lpage>74</lpage>.<pub-id pub-id-type="pmid">21265010</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liebenberg</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Gamieldien</surname><given-names>H</given-names></string-name>,
<string-name><surname>Mkhize</surname><given-names>NN</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Stability and transport of cervical cytobrushes for isolation of
mononuclear cells from the female genital tract</article-title>. <source>J Immunol
Methods</source><year>2011</year>;
<volume>367</volume>:<fpage>47</fpage>–<lpage>55</lpage>.<pub-id pub-id-type="pmid">21324321</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gohl</surname><given-names>DM</given-names></string-name>, <string-name><surname>Vangay</surname><given-names>P</given-names></string-name>, <string-name><surname>Garbe</surname><given-names>J</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Systematic improvement of amplicon marker gene methods for increased
accuracy in microbiome studies</article-title>. <source>Nat
Biotechnol</source><year>2016</year>;
<volume>34</volume>:<fpage>942</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">27454739</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DiGiulio</surname><given-names>DB</given-names></string-name>, <string-name><surname>Callahan</surname><given-names>BJ</given-names></string-name>,
<string-name><surname>McMurdie</surname><given-names>PJ</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Temporal and spatial variation of the human microbiota during
pregnancy</article-title>. <source>Proc Natl Acad Sci USA</source><year>2015</year>;
<volume>112</volume>:<fpage>11060</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">26283357</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Noël-Romas</surname><given-names>L</given-names></string-name>, <string-name><surname>Perner</surname><given-names>M</given-names></string-name>, <string-name><surname>Molatlhegi</surname><given-names>R</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Vaginal microbiome-hormonal contraceptive interactions associate with the
mucosal proteome and HIV acquisition</article-title>. <source>PLoS
Pathog</source><year>2020</year>;
<volume>16</volume>:<fpage>e1009097</fpage>.<pub-id pub-id-type="pmid">33362285</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McKinnon</surname><given-names>LR</given-names></string-name>, <string-name><surname>Nyanga</surname><given-names>B</given-names></string-name>, <string-name><surname>Kim</surname><given-names>CJ</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Early HIV-1 infection is associated with reduced frequencies of cervical
Th17 cells</article-title>. <source>J Acquir Immune Defic
Syndr</source><year>2015</year>;
<volume>68</volume>:<fpage>6</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">25296095</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Acosta-Rodriguez</surname><given-names>EV</given-names></string-name>, <string-name><surname>Rivino</surname><given-names>L</given-names></string-name>, <string-name><surname>Geginat</surname><given-names>J</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Surface phenotype and antigenic specificity of human interleukin
17-producing T helper memory cells</article-title>. <source>Nat
Immunol</source><year>2007</year>;
<volume>8</volume>:<fpage>639</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">17486092</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Duhen</surname><given-names>T</given-names></string-name>, <string-name><surname>Geiger</surname><given-names>R</given-names></string-name>, <string-name><surname>Jarrossay</surname><given-names>D</given-names></string-name>, <string-name><surname>Lanzavecchia</surname><given-names>A</given-names></string-name>,
<string-name><surname>Sallusto</surname><given-names>F</given-names></string-name></person-group>.
<article-title>Production of interleukin 22 but not interleukin 17 by a subset of human
skin-homing memory T cells</article-title>. <source>Nat.
Immunol</source><year>2009</year>;
<volume>10</volume>:<fpage>857</fpage>–<lpage>63</lpage>.<pub-id pub-id-type="pmid">19578369</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tasker</surname><given-names>C</given-names></string-name>, <string-name><surname>Pizutelli</surname><given-names>V</given-names></string-name>,
<string-name><surname>Lo</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ramratnam</surname><given-names>B</given-names></string-name>, <string-name><surname>Roche</surname><given-names>NE</given-names></string-name>, <string-name><surname>Chang</surname><given-names>TL</given-names></string-name></person-group>.
<article-title>Depot medroxyprogesterone acetate administration increases cervical CCR5
+ CD4 + T cells and induces immunosuppressive milieu at the cervicovaginal
mucosa</article-title>. <source>AIDS</source><year>2020</year>;
<volume>34</volume>:<fpage>729</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">31972606</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gosselin</surname><given-names>A</given-names></string-name>, <string-name><surname>Monteiro</surname><given-names>P</given-names></string-name>, <string-name><surname>Chomont</surname><given-names>N</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Peripheral blood CCR4<sup>+</sup> CCR6<sup>+</sup> and CXCR3<sup>+</sup>
CCR6<sup>+</sup> CD4<sup>+</sup> T cells are highly permissive to HIV-1
infection</article-title>. <source>J Immunol</source><year>2010</year>;
<volume>184</volume>:<fpage>1604</fpage>–<lpage>16</lpage>.<pub-id pub-id-type="pmid">20042588</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kader</surname><given-names>M</given-names></string-name>, <string-name><surname>Wang</surname><given-names>X</given-names></string-name>, <string-name><surname>Piatak</surname><given-names>M</given-names></string-name>, <etal>et
al</etal></person-group><article-title>α4+β7hiCD4 + memory T cells harbor most Th-17 cells and are preferentially
infected during acute SIV infection</article-title>. <source>Mucosal
Immunol</source><year>2009</year>;
<volume>2</volume>:<fpage>439</fpage>–<lpage>49</lpage>.<pub-id pub-id-type="pmid">19571800</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stieh</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Matias</surname><given-names>E</given-names></string-name>, <string-name><surname>Xu</surname><given-names>H</given-names></string-name>,
<etal>et al</etal></person-group><article-title>Th17 cells are preferentially infected very early after vaginal
transmission of SIV in macaques</article-title>. <source>Cell Host
Microbe</source><year>2016</year>;
<volume>19</volume>:<fpage>529</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">27078070</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>McKinnon</surname><given-names>LR</given-names></string-name>, <string-name><surname>Nyanga</surname><given-names>Billy</given-names></string-name>,
<string-name><surname>Chege</surname><given-names>Duncan</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Characterization of a human cervical CD4<sup>+</sup> T cell subset
coexpressing multiple markers of HIV susceptibility</article-title>. <source>J
Immunol</source><year>2011</year>;
<volume>187</volume>:<fpage>6032</fpage>–<lpage>42</lpage>.<pub-id pub-id-type="pmid">22048765</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Masson</surname><given-names>L</given-names></string-name>, <string-name><surname>Passmore</surname><given-names>J-AS</given-names></string-name>,
<string-name><surname>Liebenberg</surname><given-names>LJ</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Genital inflammation and the risk of HIV acquisition in
women</article-title>. <source>Clin Infect Dis</source><year>2015</year>;
<volume>61</volume>:<fpage>260</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">25900168</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ferreira</surname><given-names>VH</given-names></string-name>, <string-name><surname>Dizzell</surname><given-names>S</given-names></string-name>, <string-name><surname>Nazli</surname><given-names>A</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Medroxyprogesterone acetate regulates HIV-1 uptake and transcytosis but not
replication in primary genital epithelial cells, resulting in enhanced T-cell
infection</article-title>. <source>J Infect Dis</source><year>2015</year>;
<volume>211</volume>:<fpage>1745</fpage>–<lpage>56</lpage>.<pub-id pub-id-type="pmid">25538276</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Birse</surname><given-names>KD</given-names></string-name>, <string-name><surname>Romas</surname><given-names>LM</given-names></string-name>, <string-name><surname>Guthrie</surname><given-names>BL</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Genital injury signatures and microbiome alterations associated with depot
medroxyprogesterone acetate usage and intravaginal drying practices</article-title>.
<source>J Infect Dis</source><year>2016</year>;
<volume>215</volume>:<fpage>590</fpage>–<lpage>8</lpage>.</mixed-citation>
              </ref>
              <ref id="ciac284-B31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Borgdorff</surname><given-names>H</given-names></string-name>, <string-name><surname>Gautam</surname><given-names>R</given-names></string-name>, <string-name><surname>Armstrong</surname><given-names>SD</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Cervicovaginal microbiome dysbiosis is associated with proteome changes
related to alterations of the cervicovaginal mucosal barrier</article-title>.
<source>Mucosal Immunol</source><year>2016</year>;
<volume>9</volume>:<fpage>621</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">26349657</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mitchell</surname><given-names>CM</given-names></string-name>, <string-name><surname>McLemore</surname><given-names>L</given-names></string-name>, <string-name><surname>Westerberg</surname><given-names>K</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Long-term effect of depot medroxyprogesterone acetate on vaginal
microbiota, epithelial thickness and HIV target cells</article-title>. <source>J Infect
Dis</source><year>2014</year>;
<volume>210</volume>:<fpage>651</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">24652495</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jeppsson</surname><given-names>S</given-names></string-name>, <string-name><surname>Johansson</surname><given-names>EDB</given-names></string-name></person-group>.
<article-title>Medroxyprogesterone acetate, estradiol, FSH and LH in peripheral blood
after intramuscular administration of Depo-provera® to women</article-title>.
<source>Contraception</source><year>1976</year>;
<volume>14</volume>:<fpage>461</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">975831</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fotherby</surname><given-names>K</given-names></string-name>, <string-name><surname>Saxena</surname><given-names>BN</given-names></string-name>, <string-name><surname>Shrimanker</surname><given-names>K</given-names></string-name>, <etal>et
al</etal></person-group><article-title>A preliminary pharmacokinetic and pharmacodynamic evaluation of
depot-medroxyprogesterone acetate and norethisterone oenanthate</article-title>.
<source>Fertil Steril</source><year>1980</year>;
<volume>34</volume>:<fpage>131</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">7409232</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname><given-names>L</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>J</given-names></string-name>, <string-name><surname>Wang</surname><given-names>W</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Effects of three long-acting reversible contraceptive methods on HIV target
cells in the human uterine cervix and peripheral blood</article-title>. <source>Reprod
Biol Endocrinol</source><year>2019</year>;
<volume>17</volume>:<fpage>26</fpage>.<pub-id pub-id-type="pmid">30795774</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miller</surname><given-names>L</given-names></string-name>, <string-name><surname>Patton</surname><given-names>DL</given-names></string-name>, <string-name><surname>Meier</surname><given-names>A</given-names></string-name>, <string-name><surname>Thwin</surname><given-names>SS</given-names></string-name>, <string-name><surname>Hooton</surname><given-names>TM</given-names></string-name>, <string-name><surname>Eschenbach</surname><given-names>DA</given-names></string-name></person-group>.
<article-title>Depomedroxyprogesterone-induced hypoestrogenism and changes in vaginal
flora and epithelium</article-title>. <source>Mech Dev</source><year>2000</year>;
<volume>96</volume>:<fpage>431</fpage>–<lpage>9</lpage>.</mixed-citation>
              </ref>
              <ref id="ciac284-B37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Calla</surname><given-names>NEQ</given-names></string-name>, <string-name><surname>Vicetti
Miguel</surname><given-names>RD</given-names></string-name>, <string-name><surname>Boyaka</surname><given-names>PN</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Medroxyprogesterone acetate and levonorgestrel increase genital mucosal
permeability and enhance susceptibility to genital herpes simplex virus type 2
infection</article-title>. <source>Mucosal Immunol</source><year>2016</year>;
<volume>9</volume>:<fpage>1571</fpage>–<lpage>3</lpage>.<pub-id pub-id-type="pmid">27007679</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Davis</surname><given-names>ASW</given-names></string-name>, <string-name><surname>Vick</surname><given-names>SC</given-names></string-name>, <string-name><surname>Pattacini</surname><given-names>L</given-names></string-name>, <etal>et
al</etal></person-group><article-title>The human memory T cell compartment changes across tissues of the female
reproductive tract</article-title>. <source>Mucosal Immunol</source><year>2021</year>;
<volume>14</volume>:<fpage>862</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">33953338</pub-id></mixed-citation>
              </ref>
              <ref id="ciac284-B39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shanmugasundaram</surname><given-names>U</given-names></string-name>, <string-name><surname>Critchfield</surname><given-names>JW</given-names></string-name>,
<string-name><surname>Pannell</surname><given-names>J</given-names></string-name>, <etal>et
al</etal></person-group><article-title>Phenotype and functionality of CD4<sup>+</sup> and CD8<sup>+</sup> T cells
in the upper reproductive tract of healthy premenopausal women</article-title>.
<source>Am J Reprod Immunol</source><year>2014</year>;
<volume>71</volume>:<fpage>95</fpage>–<lpage>108</lpage>.<pub-id pub-id-type="pmid">24313954</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
